Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amatuximab Plus Pemetrexed and Cisplatin in Unresectable Malignant Pleural Mesothelioma (Germany Extension/Access Study)
2014-004489-85Phase 2Completed
- Sponsor
- Morphotek
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pleural mesothelioma comparing amatuximab + pemetrexed + cisplatin with placebo + pemetrexed + cisplatin (2 arms). Primary endpoint: No efficacy assessments. Started May 2015; status: completed.
02
Drugs
amatuximab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2014-004489-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004489-85.